Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/70573
Title: | Recent advances in the use of PI3K inhibitors for glioblastoma multiforme : current preclinical and clinical development | Authors: | Zhao, HF Wang, J Shao, W Wu, CP Chen, ZP To, SST Li, WP |
Issue Date: | 2017 | Source: | Molecular cancer, 2017, v. 16, 100, p. 1-16 | Abstract: | Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary tumor in the central nervous system. One of the most widely used chemotherapeutic drugs for GBM is temozolomide, which is a DNA-alkylating agent and its efficacy is dependent on MGMT methylation status. Little progress in improving the prognosis of GBM patients has been made in the past ten years, urging the development of more effective molecular targeted therapies. Hyper-activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway is frequently found in a variety of cancers including GBM, and it plays a central role in the regulation of tumor cell survival, growth, motility, angiogenesis and metabolism. Numerous PI3K inhibitors including pan-PI3K, isoform-selective and dual PI3K/mammalian target of rapamycin (mTOR) inhibitors have exhibited favorable preclinical results and entered clinical trials in a range of hematologic malignancies and solid tumors. Furthermore, combination of inhibitors targeting PI3K and other related pathways may exert synergism on suppressing tumor growth and improving patients' prognosis. Currently, only a handful of PI3K inhibitors are in phase I/II clinical trials for GBM treatment. In this review, we focus on the importance of PI3K/Akt pathway in GBM, and summarize the current development of PI3K inhibitors alone or in combination with other inhibitors for GBM treatment from preclinical to clinical studies. | Keywords: | Glioblastoma GBM PI3K MTOR |
Publisher: | BioMed Central | Journal: | Molecular cancer | ISSN: | 1476-4598 | DOI: | 10.1186/s12943-017-0670-3 | Rights: | © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. The following publication Zhao, H. F., Wang, J., Shao, W., Wu, C. P., Chen, Z. P., To, S. S. T., & Li, W. P. (2017). Recent advances in the use of PI3K inhibitors for glioblastoma multiforme : current preclinical and clinical development. Molecular Cancer, 16, 100, 1-16 is available at https://dx.doi.org/10.1186/s12943-017-0670-3 |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Zhao_Recent_Advances_Pi3K.pdf | 878.23 kB | Adobe PDF | View/Open |
Page views
97
Last Week
1
1
Last month
Citations as of Apr 21, 2024
Downloads
89
Citations as of Apr 21, 2024
SCOPUSTM
Citations
185
Last Week
1
1
Last month
Citations as of Apr 19, 2024
WEB OF SCIENCETM
Citations
179
Last Week
0
0
Last month
Citations as of Apr 25, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.